SegueTx-Pancreatic Cancer is a subsiduary of Segue Therapeutics LLC --an early-stage biotech structured around repurposing drugs for various medical conditions requiring more effective therapeutic interventions than currently available. SegueTx-Pancreatic Cancer was formed to complete preclinical studies and position for clinical trials an existing pinworm drug. The effort is to to explore efficacy of that drug for treatment of pancreatic cancer and other diseases where fibrosis plays a major role. Fibrotic-based diseases effecting the lung, heart, kidney and liver are devastating pathologies where truly effective life-extending treatments are not available. The firm is seeking FDA approval an orphan drug status for these drugs - a status that would increase their market exclusivity and reduces the time to market. Patents have been filed in US and Europe.
